NCT02000102已完成不适用
Outcomes of Diabetic Macula Edema Patients Switched to Aflibercept From Bevacizumab and/or Ranibizumab
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 14
- 试验地点
- 1
- 主要终点
- Visual Acuity
研究概览
简要总结
Patients with diabetic macular edema who were switched to aflibercept after having been treated with bevacizumab or ranibizumab were retrospectively reviewed to assess for visual acuity and anatomic outcomes.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Those patients with diabetic macular edema switched to aflibercept from bevacizumab and/or ranibizumab -
排除标准
- 未提供
研究组 & 干预措施
Diabetic Macular Edema Patients Switched to Aflibercept
干预措施: Intravitreal Injection of Aflibercept (Drug)
结局指标
主要结局
Visual Acuity
时间窗: 1 year
次要结局
- Central Subfield Thickness on Optical Coherence Tomography(1 year)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Aflibercept for Diabetic Macular Edema In Real-life Practice in GREeceDiabetic Macular EdemaNCT05683912University of Athens100
已完成
4 期
Comparison of Aflibercept Versus Ranibizumab in Management of Diabetic Macular Edema (DME)Diabetic Macular EdemaNCT04087746Minia University400
已完成
4 期
Predictors of Treatment Response to Aflibercept and Aqueous Cytokine Levels in Diabetic Macular EdemaDiabetic Macular EdemaNCT02441907Unity Health Toronto16
Unknown
4 期
Predictors of Treatment Response to Aflibercept and Aqueous Cytokine Levels in Patients With Persistent Diabetic Macular Edema Following Treatment With Ranibizumab: An Interventional Prospective StudyDiabetic Macular EdemaNCT02651168Unity Health Toronto50
已完成
4 期
Efficacy of Ranibizumab Therapy With Aflibercept in Patients With Diabetic Macular EdemaRetinal DiseasesNCT02646670Instituto de Olhos de Goiania20